Using a custom panel built for 62 pancreatic cancer genes, they found cancer specific mutations in 88% of the samples, and KRAS-specific mutations in 70% of the samples, which was consistent with the tissue-based sequencing. This evidence concerns the gene KRAS and pancreatic neoplasm.